{
    "clinical_study": {
        "@rank": "119223", 
        "acronym": "ADEQUATE", 
        "arm_group": [
            {
                "arm_group_label": "Group A - tacrolimus half-dose", 
                "arm_group_type": "Experimental", 
                "description": "Immunosuppressive strategy with 50 % reduction of Advagraf\u00ae daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.\nDrug: Tacrolimus targeted half-dose"
            }, 
            {
                "arm_group_label": "Group B - tacrolimus unchanged dose", 
                "arm_group_type": "Experimental", 
                "description": "Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf\u00ae and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose"
            }
        ], 
        "brief_summary": {
            "textblock": "This prospective, interventional, open label, randomized, multicenter study was designed to\n      determine the risk/benefit ratio of a 50 % reduction of Advagraf\u00ae daily dose, 4 months after\n      transplantation. Randomized patients are to be stable with their tacrolimus daily dose\n      required to reach targeted tacrolimus trough levels. Based on Month-3 eligibility\n      assessments, patients will be randomized in two groups (1:1): patients with 50 % reduction\n      of the daily dose of Advagraf\u00ae 4 months after transplantation, and patients kept on their\n      usual dose. The benefit/risk ratio will include the assessment of renal function,\n      histological lesions from both alloreactivity and CNI nephrotoxicity, and safety data\n      (metabolic and infectious diseases)."
        }, 
        "brief_title": "Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE)", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "De Novo Transplant Disease", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 18 et 70 years\n\n          -  Patient accepting to give a written informed consent\n\n          -  Recipients of a first renal allograft\n\n          -  Cadaver or living transplantation or living (non HLA identical) donor with compatible\n             ABO blood type.\n\n          -  Absence of positive DSA using Luminex\u00ae, MFI>1,000\n\n          -  Negative cross-match in cytotoxicity\n\n          -  Patient without difficulty to understand and communicate with the investigator and\n             his collaborators\n\n          -  Patient entitled to Health System benefits or other such benefits.\n\n        Exclusion Criteria:\n\n          -  Multiple organ transplantation\n\n          -  Recipients of a dual kidney transplant\n\n          -  Previous renal allograft\n\n          -  History of any other transplantation\n\n          -  Receiving a graft from a non-heart-beating donor\n\n          -  Patient BMI > 35\n\n          -  Patients with evidence of severe liver disease, including abnormal liver profile\n             (AST, ALT, or total bilirubin > 3 times upper limit of normal) at screening.\n\n          -  Significant severe infection, active peptic ulcer and/or difficulty to absorb oral\n             drugs (active upper gastro-intestinal tract malabsorption syndrome)\n\n          -  HIV-positive patients, or with an active B or C hepatitis\n\n          -  Patients with de novo malignancy prior to transplantation, other than efficiently\n             treated basal or squamous cell carcinoma of the skin.\n\n          -  Leucocyte count lower than 2500/mm3\n\n          -  Female patients who are pregnant, lactating or of child bearing potential and not\n             practicing an approved method of birth control.\n\n          -  Known allergy or intolerance to basiliximab, tacrolimus, macrolide antibiotics,\n             corticosteroids, or mycophenolate mofetil or any of the product excipients\n\n          -  Participation in a clinical trial or expanded access trial with an investigational\n             drug within 4 weeks prior to enrollment or concomitantly with this study\n\n          -  Any clinical condition which, in the opinion of the investigator, would not allow\n             safe completion of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "286", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744470", 
            "org_study_id": "PHAO2011/YL/ADEQUATE", 
            "secondary_id": "2011-003184-29"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A - tacrolimus half-dose", 
                "intervention_name": "Tacrolimus targeted half-dose", 
                "intervention_type": "Drug", 
                "other_name": "Advagraf\u00ae"
            }, 
            {
                "arm_group_label": "Group B - tacrolimus unchanged dose", 
                "intervention_name": "Tacrolimus targeted plain dose", 
                "intervention_type": "Drug", 
                "other_name": "Advagraf\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tacrolimus"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Renal", 
            "Transplantation", 
            "Tacrolimus"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Amiens", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Sud"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France"
                    }, 
                    "name": "CHU de Angers"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bois-Guillaume", 
                        "country": "France", 
                        "zip": "76130"
                    }, 
                    "name": "H\u00f4pital Bois-Guillaume"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brest", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Cavale Blanche"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France"
                    }, 
                    "name": "CHU de Caen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clermont-Ferrand", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Gabriel Montpied"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Le Kremlin Bic\u00eatre", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Bic\u00eatre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Limoges", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Dupuytren"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Archet II"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75015"
                    }, 
                    "name": "HEGP"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Necker"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reims", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Maison Blanche"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Pontchaillou"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Civil"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France"
                    }, 
                    "name": "CHU de Toulouse"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France"
                    }, 
                    "name": "CHRU de Tours"
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety Outcome of Two Different Targets of Advagraf\u00ae Trough Levels Between 4 Months and 12 Months After Transplantation Among de Novo Renal Transplant Recipients.", 
        "overall_official": {
            "affiliation": "University Hospital, Tours", 
            "last_name": "Yvon LEBRANCHU", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Renal function at one year post transplantation estimated by the glomerular filtration rate (GFR) using MDRD 4 (Modification Diet in Renal Disease). Crude difference in renal function at one year between groups and the change of renal function between 4 months and one year in each group will be analyzed and compared.", 
            "measure": "Renal function at one year post transplantation", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744470"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Routine graft histology at M12 assessed using Banff 2009 classification, with specific analysis of interstitial fibrosis (IF) using numeric quantification", 
                "measure": "To determine and compare according to randomized group", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Glucose metabolism at M4 and M12", 
                "measure": "To determine and compare according to randomized group", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Infection rate including BKV and CMV at M4 and M12", 
                "measure": "To determine and compare according to randomized group", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Presence and intensity of Donor Specific Antibody (DSA) at M3 and M12", 
                "measure": "To determine and compare according to randomized group", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Incidence of biopsy proven acute rejection episode at M12", 
                "measure": "To determine and compare according to randomized group", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Graft and patient survival at M12", 
                "measure": "To determine and compare according to randomized group", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Overall safety assessment", 
                "measure": "To determine and compare according to randomized group", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "University Hospital, Tours", 
        "sponsors": {
            "collaborator": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University Hospital, Tours", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}